Literature DB >> 22213008

Trypsin-like proteolytic contamination of commercially available psa purified from human seminal fluid.

Michael L Manning1, Maya Kostova, Simon A Williams, Samuel R Denmeade.   

Abstract

BACKGROUND: Prostate-Specific Antigen (PSA) is a serine protease whose expression is maintained in all stages of prostate cancer. A role for PSA in the pathobiology for prostate cancer has not been firmly established. Experimental studies to date support a role for PSA through mechanisms such as release or processing of growth factors and degradation of the extracellular matrix. Exposure of prostate cancer cells to exogenous PSA also results in gene expression changes. These in vitro and biochemical assays rely on the use of commercially available PSA. Contamination of these commercial preparations can significantly impact the results of these in vitro studies.
METHODS: We characterized PSA and trypsin-like activity of PSA preparations obtained from three commercial sources: Calbiochem, Fitzgerald, and AbD Serotec. Silver stained gels were used to compare the purity of each preparation and mass spectrometry was performed to characterize contaminating proteases.
RESULTS: PSA activity varied between PSA preparations with AbD Serotec PSA having highest degree of activity. Significant trypsin-like activity, which was inhibited by aprotinin, was observed in PSA preparations from Calbiochem and Fitzgerald, but not AbD Serotec. These former two PSA preparations also contained the greatest degree of non-PSA contaminants by silver stain and mass spectrometry.
CONCLUSIONS: Commercially available preparations of PSA contain contaminating proteins, including trypsin-like protease activity, that could potentially complicate the interpretation of results obtained from in vitro studies assessing PSA proteolysis of potential protein substrates and effects of PSA on gene expression.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22213008      PMCID: PMC3419387          DOI: 10.1002/pros.22474

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  40 in total

Review 1.  The new human tissue kallikrein gene family: structure, function, and association to disease.

Authors:  G M Yousef; E P Diamandis
Journal:  Endocr Rev       Date:  2001-04       Impact factor: 19.871

2.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search.

Authors:  Andrew Keller; Alexey I Nesvizhskii; Eugene Kolker; Ruedi Aebersold
Journal:  Anal Chem       Date:  2002-10-15       Impact factor: 6.986

3.  Proteomic analysis of human prostasomes.

Authors:  Angelita G Utleg; Eugene C Yi; Tao Xie; Paul Shannon; James T White; David R Goodlett; Leroy Hood; Biaoyang Lin
Journal:  Prostate       Date:  2003-07-01       Impact factor: 4.104

4.  Enzymatically active prostate-specific antigen promotes growth of human prostate cancers.

Authors:  Simon A Williams; Christine A Jelinek; Ivan Litvinov; Robert J Cotter; John T Isaacs; Samuel R Denmeade
Journal:  Prostate       Date:  2011-03-10       Impact factor: 4.104

5.  Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo.

Authors:  A H Fortier; J W Holaday; H Liang; C Dey; D K Grella; J Holland-Linn; H Vu; S M Plum; B J Nelson
Journal:  Prostate       Date:  2003-08-01       Impact factor: 4.104

6.  Purification of a human prostate specific antigen.

Authors:  M C Wang; L A Valenzuela; G P Murphy; T M Chu
Journal:  Invest Urol       Date:  1979-09

7.  A comprehensive characterization of the peptide and protein constituents of human seminal fluid.

Authors:  Kim Y C Fung; L Michael Glode; Spencer Green; Mark W Duncan
Journal:  Prostate       Date:  2004-10-01       Impact factor: 4.104

8.  Prostate cancer cell adhesion to bone marrow endothelium: the role of prostate-specific antigen.

Authors:  Victor I Romanov; Terry Whyard; Howard L Adler; Wayne C Waltzer; Stanley Zucker
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

9.  Prostate-specific antigen (PSA)-mediated proliferation, androgenic regulation and inhibitory effects of LY312340 in HOS-TE85 (TE85) human osteosarcoma cells.

Authors:  Christian M Gygi; Ilan Y Leibovitch; Robert Adlington; Jack E Baldwin; Beining Chen; William Mccoull; Gareth J Pritchard; Gerald W Becker; Eric P Dixon; Sheila P Little; Debra M Sutkowski; Carroll Teater; Blake Lee Neubauer
Journal:  Anticancer Res       Date:  2002 Sep-Oct       Impact factor: 2.480

Review 10.  An overview of the kallikrein gene families in humans and other species: emerging candidate tumour markers.

Authors:  George M Yousef; Eleftherios P Diamandis
Journal:  Clin Biochem       Date:  2003-09       Impact factor: 3.281

View more
  4 in total

1.  PSA-alpha-2-macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones.

Authors:  Maya B Kostova; William Nathaniel Brennen; David Lopez; Lizamma Anthony; Hao Wang; Elizabeth Platz; Samuel R Denmeade
Journal:  Prostate       Date:  2018-04-16       Impact factor: 4.104

2.  Proteolytic activity of prostate-specific antigen (PSA) towards protein substrates and effect of peptides stimulating PSA activity.

Authors:  Johanna M Mattsson; Suvi Ravela; Can Hekim; Magnus Jonsson; Johan Malm; Ale Närvänen; Ulf-Håkan Stenman; Hannu Koistinen
Journal:  PLoS One       Date:  2014-09-19       Impact factor: 3.240

3.  Comprehensive role of prostate-specific antigen identified with proteomic analysis in prostate cancer.

Authors:  Haoyong Li; Zhe Ma; Zhifei Che; Qi Li; Jinfeng Fan; Zhiyan Zhou; Yaoxi Wu; Yingxia Jin; Peiyu Liang; Xianping Che
Journal:  J Cell Mol Med       Date:  2020-07-27       Impact factor: 5.310

Review 4.  KLK3 in the Regulation of Angiogenesis-Tumorigenic or Not?

Authors:  Hannu Koistinen; Jaana Künnapuu; Michael Jeltsch
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.